What is HRTX's health score?

HERON THERAPEUTICS, INC. /DE/ (HRTX) has a TradeApes health score of 39 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is HRTX's estimated fair value?

Based on our 5-year discounted cash flow model, HERON THERAPEUTICS, INC. /DE/'s estimated fair value is $3.49 per share, representing a 618.0% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is HRTX undervalued or overvalued?

Our model currently rates HRTX as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for HRTX... Refresh in a moment for the full analysis.

HERON THERAPEUTICS, INC. /DE/ (HRTX)

Healthcare Undervalued low weak

$0.49

Updated: 2026-06-04

TradeApes Score

Financial Strength

10 Stressed

Operating Trend

48 Mixed

Relative Value

40 Weak

Capital Allocation

65 Healthy

Risk

50 Mixed

Est. Fair Value $3.49

DCF Upside +618.0%

Sector Rank #2149 of 6497

Key Findings

+ Active buybacks — share count declining, capital returned to owners

Unlock Full Report →

− High leverage — net debt/EBITDA between 3× and 5×

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.